Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 23, 2025Bulletin of the National Research Centre/Bulletin of the National Research CenterOpen Access

Therapeutic efficacy and safety of praziquantel for intestinal schistosomiasis treatment among patients receiving rifampicin-based anti-TB drugs in the Lake Victoria zone, Tanzania

View Full Paper
Ask AI
Bookmark
Share

Authors

RMRajabu Hussein MnkugwePSPhilip SasiSKSafari Kinung’hi

Discussion

Loading...

Member takes

Overview

Prospective study evaluates praziquantel efficacy and safety in patients on rifampicin-based therapies, suggesting drug interaction issues.

Key Points

  • Praziquantel showed low parasitological cure rates of 49% among patients with schistosomiasis-TB coinfection, indicating efficacy challenges.
  • A total of 540 patients screened, with 159 enrolled; the egg reduction rate was 76.4%, reflecting partial efficacy in the cohort.
  • The study utilized a prospective design, assessing cure rates and adverse events post-treatment with a single dose of praziquantel.
  • Future research is necessary to understand drug-drug interactions, as the current study lacked a comparison group and plasma concentration data.

Cite This Study

Mnkugwe et al. (2025) studied this question.

synapsesocial.com/papers/68d43d6f713b0b5dfea7d284https://doi.org/10.1186/s42269-025-01357-9
View Full Paper
Ask AI
Bookmark
Share